Elranatamab
Phase 3Monoclonal antibody
PfizerElranatamab is a monoclonal antibody that works as a T Cell Surface Glycoprotein CD3 Binding Agent; Tumor Necrosis Factor Receptor Superfamily Member 17 Binding Agent.[2] It is being investigated across 13 indications, with its most advanced program in Phase 3.[1]
Elranatamab is one of 128 small molecule programs targeting Radiotherapy-Induced Immune Priming. It is currently in Phase 3.
13
Indications
46
Total Trials
37
Active Trials
127
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1TALVEY
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Cytosar
TevaPhase 3
Busulfex
Akero TherapeuticsPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma27 trials
Show 24 more trials
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled
Elranatamab5 trials
Multiple Myeloma (MM)2 trials
Relapsed or Refractory1 trial
10 more indications
Relapsed Refractory Multiple Myeloma (RRMM)1 trial
Smoldering Multiple Myeloma1 trial
Refractory Multiple Myeloma1 trial
Hemophilia A With Inhibitor1 trial
A Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety and Efficacy of Elranatamab for Inhibitor Eradication in Patients With Moderate-to-Severe Hemophilia A With Inhibitors and Poor Prognosis for Inhibitor Eradication
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07788469·20 enrolled
AL amyloidosis1 trial
Multiple Myeloma, Newly Diagnosed1 trial
Myeloma Multiple1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Elranatamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]